Across TCGA pan-cancer cohorts, HES7 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HES7 data layer compared with 29 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher HES7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HES7 expression acts as an unfavorable survival marker.
COAD are the cancer types where HES7 Mutation most reproducibly stratifies survival.